These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8633664)

  • 1. Placental transfer of milrinone in the nonhuman primate (baboon).
    Atkinson BD; Fishburne JI; Hales KA; Levy GH; Rayburn WF
    Am J Obstet Gynecol; 1996 Mar; 174(3):895-6. PubMed ID: 8633664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal loading dose of milrinone for weaning from cardiopulmonary bypass.
    De Hert SG; Vermeyen KM
    Anesth Analg; 1996 May; 82(5):1110-1. PubMed ID: 8610889
    [No Abstract]   [Full Text] [Related]  

  • 3. A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure.
    Pflugfelder PW; O'Neill BJ; Ogilvie RI; Beanlands DS; Tanser PH; Tihal H; Mizgala HF; Fitchett DH; Kostuk WJ
    Can J Cardiol; 1991; 7(1):5-10. PubMed ID: 2025794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hemodynamic effects of milrinone on patients with chronic congestive heart failure: a multicenter study. Cooperative Group for Phase II Clinical Trial of Milrinone].
    Zhonghua Nei Ke Za Zhi; 1995 Sep; 34(9):599-602. PubMed ID: 8697925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery.
    Bailey JM; Levy JH; Kikura M; Szlam F; Hug CC
    Anesthesiology; 1994 Sep; 81(3):616-22. PubMed ID: 8092507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of the hemodynamic and pharmacokinetic profile of intravenous milrinone in the anesthetized dog.
    Alousi AA; Iwan T; Edelson J; Biddlecome C
    Arch Int Pharmacodyn Ther; 1984 Jan; 267(1):59-66. PubMed ID: 6721624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.
    Baim DS; McDowell AV; Cherniles J; Monrad ES; Parker JA; Edelson J; Braunwald E; Grossman W
    N Engl J Med; 1983 Sep; 309(13):748-56. PubMed ID: 6888453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group.
    Karlsberg RP; DeWood MA; DeMaria AN; Berk MR; Lasher KP
    Clin Cardiol; 1996 Jan; 19(1):21-30. PubMed ID: 8903534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.
    Jaski BE; Fifer MA; Wright RF; Braunwald E; Colucci WS
    J Clin Invest; 1985 Feb; 75(2):643-9. PubMed ID: 3973022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of the use of milrinone in the treatment of acute crisis in patients with congestive heart failure].
    Gun C; Piegas LS; Bianco AC; Freire RB; Ramos RF; Timerman A
    Arq Bras Cardiol; 1995 Sep; 65(3):255-8. PubMed ID: 8579514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Milrinone, a new agent for the treatment of congestive heart failure.
    Hasegawa GR
    Clin Pharm; 1986 Mar; 5(3):201-5. PubMed ID: 3514085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of intravenous inotropic therapy in the home.
    McCloskey WW
    Am J Health Syst Pharm; 1998 May; 55(9):930-5; quiz 953-4. PubMed ID: 9588252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term intravenous milrinone for severe congestive heart failure: the good, bad, and not so good.
    Varriale P; Ramaprasad S
    Pharmacotherapy; 1997; 17(2):371-4. PubMed ID: 9085331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Milrinone. A preliminary review of its pharmacological properties and therapeutic use.
    Young RA; Ward A
    Drugs; 1988 Aug; 36(2):158-92. PubMed ID: 3053125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous milrinone: therapeutic responses in heart failure.
    Braunwald E
    Am Heart J; 1991 Jun; 121(6 Pt 2):1937-8. PubMed ID: 2035423
    [No Abstract]   [Full Text] [Related]  

  • 16. Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure.
    Woolfrey SG; Hegbrant J; Thysell H; Fox PA; Lendrem DW; Lockwood GF; Lasher K; Rogers J; Greenslade D
    J Pharm Pharmacol; 1995 Aug; 47(8):651-5. PubMed ID: 8583366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by beta-adrenergic blockade.
    Travill CM; Pugh S; Noble MI
    Clin Ther; 1994; 16(5):783-92. PubMed ID: 7859237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Criteria for use of intravenous milrinone in adult inpatients.
    Shubert J; Mancano MA; Pina IL; Milfred SK
    Am J Health Syst Pharm; 1995 Sep; 52(17):1918-9. PubMed ID: 8528858
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of milrinone in plasma using solid-phase extraction and high-performance liquid chromatography.
    Oddie CJ; Jackman GP; Bobik A
    J Chromatogr; 1986 Jan; 374(1):209-14. PubMed ID: 3949932
    [No Abstract]   [Full Text] [Related]  

  • 20. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.
    Colucci WS; Wright RF; Jaski BE; Fifer MA; Braunwald E
    Circulation; 1986 Mar; 73(3 Pt 2):III175-83. PubMed ID: 3510774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.